VExUS in Ards Patients and Association with AKI
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jan 30, 2025
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "VExUS in ARDS Patients and Association with AKI," is looking to understand how common venous congestion is in patients with a serious lung condition known as Acute Respiratory Distress Syndrome (ARDS). Researchers will use a special ultrasound technique called venous Doppler to measure blood flow and develop a scoring system (VExUS score) to assess this congestion. The goal is to learn more about how this condition relates to kidney health.
To participate in this study, individuals must be at least 18 years old and diagnosed with moderate to severe ARDS, requiring certain medications to support their heart function and receiving mechanical breathing support for less than two days. However, those with severe kidney problems, certain liver diseases, or specific heart conditions, as well as pregnant women and those who cannot provide consent, will not be eligible. Participants can expect to undergo some non-invasive ultrasound testing to help gather the necessary data for this research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients ≥18 years old
- • Moderate to severe ARDS according to the Berlin definition
- • Requiring catecholamine support
- • Undergoing invasive mechanical ventilation for less than 48 hours
- Exclusion Criteria:
- • Patients presenting with acute kidney injury KDIGO III requiring renal replacement therapy before the initial ultrasound evaluation
- • Requirement for veno-venous or veno-arterial ECMO circulatory support before inclusion
- • Patients with end-stage chronic kidney disease, on dialysis, and/or kidney transplant recipients
- • History of Child C cirrhosis and/or liver transplantation and/or portal hypertension
- • History of portal thrombosis
- • Known history of pulmonary hypertension
- • Pregnant women
- • Patients under legal protection
- • Patients who have expressed opposition to participating in the research
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Creteil Cedex, Val De Marne, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported